The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of thymidine kinase 1 expression on prognosis and treatment outcomes in refractory metastatic colorectal cancer: Results from two randomized studies of TAS-102 versus a placebo.
 
Takayuki Yoshino
Research Funding - Boehringer Ingelheim (Inst); GlaxoSmithKline K.K. (Inst)
 
Eiji Shinozaki
No Relationships to Disclose
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Bristol-Myers Squibb Japan (Inst)
 
Yoshito Komatsu
Honoraria - Bayer; Novartis; Pfizer
Speakers' Bureau - Bayer; Chugai Pharma; Lilly; Merck; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Bayer; Chugai Pharma; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Pharmaceutical
 
Tomohiro Nishina
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical (Inst)
 
Hideo Baba
No Relationships to Disclose
 
Akihito Tsuji
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Merck Serono; Taiho Pharmaceutical; Takeda
Speakers' Bureau - Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Takeda
 
Yasushi Tsuji
Honoraria - Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Medicon; Merck; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Kensei Yamaguchi
Speakers' Bureau - Chugai Pharma; Lilly; Merck; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Naotoshi Sugimoto
No Relationships to Disclose
 
Tadamichi Denda
No Relationships to Disclose
 
Kei Muro
Honoraria - Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Tetsuji Takayama
Research Funding - Taiho Pharmaceutical
 
Taito Esaki
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Yasuo Hamamoto
No Relationships to Disclose
 
Toshikazu Moriwaki
Honoraria - Chugai Pharma; Merck; Novartis; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst); MSD (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Yasuhiro Shimada
Honoraria - Chugai Pharma; Lilly; Taiho Pharmaceutical; Takeda; Takeda; Yakult Pharmaceutical
Research Funding - Lilly (Inst); Merck Serono (Inst); Taiho Pharmaceutical (Inst)
 
Masahiro Goto
No Relationships to Disclose
 
Takanori Tanase
Employment - Taiho Pharmaceutical
Stock and Other Ownership Interests - Taiho Pharmaceutical
 
Atsushi Ohtsu
Employment - Celgene (I)
Research Funding - Bristol-Myers Squibb